

Figure S1. The expression of DNASE1 is associated with survival in (A) BLCA, (B) KIRC, (C) PAAD and (D) THYM. BLCA, bladder urothelial carcinoma; KIRC, kidney renal clear cell carcinoma; PAAD, pancreatic adenocarcinoma; THYM, thymoma.




Figure S2. The expression of DNASE1L1 is associated with survival in (A) LAML, (B) LGG, (C) SARC, (D) UVM, (E) ACC and (F) GBM. LAML, acute myeloid leukemia; LGG, brain lower grade glioma; SARC, sarcoma; UVM, uveal melanoma; ACC, adrenocortical carcinoma; GBM, glioblastoma multiforme.




Figure S3. The expression of DNASE1L2 is associated with survival (A) CESC, (B) COAD, (C) KIRC, (D) MESO, (E) PAAD, (F) UVM, (G) ACC and (H) BLCA. CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD, colon adenocarcinoma; KIRC, kidney renal clear cell carcinoma; MESO, mesothelioma; PAAD, pancreatic adenocarcinoma; UVM, uveal melanoma; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma.




Figure S4. The expression of DNASE1L3 is associated with survival (A) PCPG, (B) SARC, (C) UVM, (D) ACC, (E) CESC, (F) KICH, (G) KIRC, (H) KIRP, (I) LIHC, (J) LUAD and (K) PAAD. PCPG, pheochromocytoma and paraganglioma; SARC, sarcoma; UVM, uveal melanoma; ACC, adrenocortical carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; PAAD, pancreatic adenocarcinoma.




Figure S5. The expression of DNASE2 is associated with survival in some cancers. (A) SARC, (B) SKCM, (C) KICH, (D) LGG and (E) MESO. SARC, sarcoma; SKCM, skin cutaneous melanoma; KICH, kidney chromophobe; LGG, brain lower grade glioma; MESO, mesothelioma.




Figure S6. The expression of DNASE2B is associated with survival (A) KIRP, (B) LGG, (C) LUAD, (D) SKCM, (E) UVM, (F) BLCA, (G) DLBC and (H) KIRC. KIRP, kidney renal papillary cell carcinoma; LGG, brain lower grade glioma; LUAD, lung adenocarcinoma; SKCM, skin cutaneous melanoma; UVM, uveal melanoma; BLCA, bladder urothelial carcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; KIRC, kidney renal clear cell carcinoma.

